Loading...
XASXCYP
Market cap32mUSD
Jan 09, Last price  
0.24AUD
1D
-2.08%
1Q
-2.08%
Jan 2017
-67.81%
IPO
-94.66%
Name

Cynata Therapeutics Ltd

Chart & Performance

D1W1MN
XASX:CYP chart
P/E
—
P/S
22.86
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.38%
Rev. gr., 5y
12.09%
Revenues
2m
+39.98%
0350,5650113,879222,936162,45233,96425,058285,5841,099,7131,748,8741,375,1351,308,5527,011,5531,546,0527,770,4251,654,3102,315,643
Net income
-10m
L-31.75%
0-1,486,743-1,101,260-2,116,125-2,564,979-1,542,307-915,701-3,039,663-3,712,077-4,939,471-4,553,536-4,566,134-8,472,146-3,639,100-7,689,683-5,445,172-14,277,495-9,744,709
CFO
-10m
L-30.26%
00000-765,765-1,853,693-2,602,346-4,353,936-4,048,190-4,061,916-6,759,077-3,387,679-5,163,109-3,298,331-14,282,729-9,960,561
Earnings
Feb 21, 2025

Profile

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
URL
https://www.cynata.com/
IPO date
Dec 20, 2007
Employees
0
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
2,316
39.98%
1,654
-78.71%
7,770
402.60%
Cost of revenue
8,962
15,906
13,165
Unusual Expense (Income)
NOPBT
(6,646)
(14,252)
(5,395)
NOPBT Margin
Operating Taxes
(2,316)
(1,654)
(833)
Tax Rate
NOPAT
(4,331)
(12,598)
(4,562)
Net income
(9,745)
-31.75%
(14,277)
162.20%
(5,445)
-29.19%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,407
BB yield
-35.32%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(6,205)
(16,167)
(23,798)
Cash flow
Cash from operating activities
(9,961)
(14,283)
(3,298)
CAPEX
Cash from investing activities
Cash from financing activities
6,724
210
FCF
(4,331)
(12,598)
(4,562)
Balance
Cash
6,205
16,167
23,798
Long term investments
Excess cash
6,090
16,085
23,410
Stockholders' equity
7,217
16,733
23,960
Invested Capital
1,128
649
551
ROIC
ROCE
EV
Common stock shares outstanding
179,632
145,092
143,277
Price
0.30
136.00%
0.13
-65.28%
0.36
-28.71%
Market cap
52,991
192.18%
18,137
-64.84%
51,580
-21.69%
EV
46,786
1,969
27,782
EBITDA
(6,646)
(13,972)
(5,115)
EV/EBITDA
Interest
Interest/NOPBT